Treatment of clozapine-associated weight gain: a systematic review
Autor: | Diane H. Fredrikson, Alasdair M. Barr, Ric M. Procyshyn, Zachary Whitney |
---|---|
Rok vydání: | 2015 |
Předmět: |
Psychosis
medicine.medical_specialty medicine.medical_treatment Psychological intervention Weight Gain Bioinformatics Extrapyramidal symptoms medicine Humans Pharmacology (medical) Antipsychotic drug Psychiatry Antipsychotic Clozapine Randomized Controlled Trials as Topic Pharmacology business.industry General Medicine medicine.disease Schizophrenia medicine.symptom business Weight gain Antipsychotic Agents medicine.drug |
Zdroj: | European Journal of Clinical Pharmacology. 71:389-401 |
ISSN: | 1432-1041 0031-6970 |
Popis: | Clozapine is an antipsychotic drug with superior efficacy in treatment-resistant schizophrenia. Clozapine is associated with a low likelihood of extrapyramidal symptoms and other neurological side-effects but a high propensity to induce weight gain and general metabolic dysregulation. Various pharmacological and behavioral treatment approaches for reducing clozapine-associated weight gain exist in the literature; however, there are currently no clear clinical guidelines as to which method is preferred. The aim of the current review is to systematically summarize studies that have studied both pharmacological and non-pharmacological interventions to attenuate or reverse clozapine-associated weight gain.A systematic review of EMBASE and MEDLINE databases of all articles published prior to January 2014 was conducted. Seventeen studies were identified as meeting inclusion criteria and included in the review.Aripiprazole, fluvoxamine, metformin, and topiramate appear to be beneficial; however, available data are limited to between one and three randomized controlled trials per intervention. Orlistat shows beneficial effects, but in males only. Behavioral and nutritional interventions also show modest effects on decreasing clozapine-associated weight gain, although only a small number of such studies exist.While a number of pharmacological interventions can produce modest weight loss, each may be associated with negative side effects, which should be considered before beginning treatment. Given the pressing need to improve cardiometabolic health in most clozapine-treated patients, substantially more research is needed to develop sound clinical practice guidelines for the treatment of clozapine-associated weight gain. |
Databáze: | OpenAIRE |
Externí odkaz: |